Mabvax Therapeutics Holdings Inc (MBVX) 0.5800 $MBVX
MabVax Therapeutics Launches Second Investigational Site with Sarah Cannon Research Institute in Ongoing Phase I Clinical Trial to Evaluate New Treatment for Pancreatic Cancer
PR Newswire - Mon Jun 13, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the initiation of a second investigational Phase I site for MVT-5873 (HuMab-5B1) with Sarah Cannon Research Institute through its network of research sites. The product is for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. In addition to the Sarah Cannon Research Institute at Tennessee Oncology site in Nashville, Tenn., patient enrollment in the Phase I trial is underway within Sarah Cannon Research Institute at Florida Cancer Specialists in Sarasota, Fla.
MabVax Therapeutics Expands Patient Enrollment in Phase I Trial for Treatment of Pancreatic Cancer to Memorial Sloan Kettering Cancer Center
PR Newswire - Tue Jun 07, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the initiation of patient enrollment at Memorial Sloan Kettering Cancer Center (MSK) in the Phase I clinical trial evaluating its leading clinical development product MVT-5873 (HuMab-5B1) as a therapeutic treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. This is the second investigational site in the Phase I trial with patient recruitment currently underway at the Sarah Cannon Research Institute in Nashville, TN. MabVax previously announced receipt of authorization to proceed on the Investigational New Drug (IND) application filed from U.S. Food and Drug Administration (FDA).
MabVax Therapeutics' Antibody Discovery Platform and HuMab-5B1 Cancer Therapeutic Featured in Presentation at America's Antibody Congress
PR Newswire - Thu May 19, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that Paul Maffuid, PhD, Executive Vice President of Research and Development, will discuss MabVax's unique approach to the discovery of fully human antibodies to cancer antigens and the resulting lead HuMab-5B1 clinical projects in a presentation at America's Antibody Congress in San Diego on May 19-20, 2016.
MabVax Therapeutics' HuMab-5B1 Cancer Therapeutic Featured in Presentation at AACR Special Meeting on Pancreatic Cancer
PR Newswire - Mon May 16, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that its lead cancer therapeutic HuMab-5B1 (MVT-5873) was featured in a poster presentation on May 13th at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, held in Orlando, Florida. MVT-5873 is currently being evaluated in an open-label, multicenter, dose-escalation Phase I clinical trial as a single agent and in combination with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.
MabVax Therapeutics' Fully Human Antibody Approach to Cancer Therapeutics and Imaging Featured in Three Presentations at AACR Annual Meeting in New Orleans
PR Newswire - Mon Apr 18, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that its fully human antibody approach to cancer therapeutics and imaging will be featured in three separate poster presentations at the American Association for Cancer Research (AACR) Annual Meeting currently underway in New Orleans.
MabVax Therapeutics Holdings Hires Paul Resnick, M.D. as Chief Business Officer
PR Newswire - Fri Apr 15, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the hiring of Paul Resnick, M.D., M.B.A. to the newly created position of Vice President and Chief Business Officer, responsible for corporate development, including engaging with large pharmaceutical and biotechnology companies on potential licensing and collaboration arrangements for our products under development.
MabVax Therapeutics Initiates Phase I Trial of HuMab-5B1 for Treatment of Pancreatic Cancer
PR Newswire - Mon Mar 21, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announced initiation of a phase I clinical trial of HuMab-5B1 for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. The CA19-9 target is expressed on more than 90% of pancreatic cancers and is a validated biomarker for the disease. The Company filed an Investigational New Drug (IND) application for this product on November 30, 2015 and received U.S. Food and Drug Administration (FDA) authorization to proceed with the study on December 24, 2015.
UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.80 (+0.19), CDXC: 5.07 (-0.24)
MabVax Therapeutics to Present at the ROTH Conference
PR Newswire - Thu Mar 10, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that President and Chief Executive Officer David Hansen is scheduled to present a corporate overview at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 11:00 a.m. Pacific time (2:00 p.m. Eastern time). The conference is being held at The Ritz Carlton Laguna Niguel hotel in Dana Point, Calif.
OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.80 (+0.19), CDXC: 5.07 (-0.24)
MabVax Therapeutics to Present at BIO CEO & Investor Conference
PR Newswire - Wed Feb 03, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that President and Chief Executive Officer David Hansen is scheduled to present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). The conference is being held at The Waldorf Astoria New York hotel in New York City.
MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer
PR Newswire - Mon Feb 01, 9:37AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration (FDA) authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. The Company filed an Investigational New Drug (IND) application for this trial with the FDA on December 29, 2015. MabVax previously announced receipt of FDA authorization for a Phase I trial with HuMab-5B1 as a therapeutic treatment for patients with pancreatic cancer, and patient enrollment in both Phase I trials is expected to commence in the first quarter of 2016.
World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zbk4w/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Small-Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Small-Cell Lung Cancer - Overview - Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis - Small-Cell Lung Cancer - Therapeutics under Development by Companies - Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Small-Cell Lung Cancer - Products under Development by Companies - Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Andarix Pharmaceuticals, Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - G1 Therapeutics, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Karyopharm Therapeutics, Inc. - Kolltan Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - MEI Pharma, Inc. - Merck & Co., Inc. - NanoSmart Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Novartis AG - Pfizer Inc. - Polaris Pharmaceuticals, Inc. - Rexahn Pharmaceuticals, Inc. - Spectrum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3z...lcell_lung
RNN: 0.26 (-0.01), PFE: 34.75 (-0.04), AMGN: 152.30 (+0.40), SPPI: 6.82 (unch), BIND: 0.42 (-0.01), LLY: 74.25 (+0.54), BMY: 71.73 (-0.84), GSK: 40.57 (+0.53), MEIP: 1.33 (+0.05), MRK: 57.50 (+1.41), ABBV: 60.90 (+0.50), NVS: 76.89 (+0.51), KPTI: 8.06 (+0.15), ARRY: 3.26 (+0.01), EXEL: 7.55 (+0.17)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
PCYC: 261.25 (+1.70), AMPE: 3.50 (+0.06), GSK: 40.57 (+0.53), MEIP: 1.33 (+0.05), AAAP: 29.00 (-0.57), MACK: 6.33 (+0.02), PGNX: 4.74 (+0.11), BLCM: 12.74 (+0.30), CYCC: 5.33 (-0.43), RXDX: 5.43 (-0.17), MRK: 57.50 (+1.41), AZN: 27.63 (+0.26), JUNO: 42.94 (-0.15), CBLI: 2.58 (-0.03), NVS: 76.89 (+0.51), CELGZ: 1.33 (-0.07)
MabVax Therapeutics Holdings Executes a Debt Facility for up to $10 million
PR Newswire - Tue Jan 19, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company announced today that it has closed on the first part of a financing agreement with a leading life sciences and healthcare lender. The financing agreement will provide the Company with up to $10 million in senior secured debt financing. The Company received an initial loan of $5 million, before approximately $381,000 in issuances costs, with an additional $5 million to be released contingent upon achieving certain milestones. The net proceeds of the initial tranche of debt financing will supplement the Company's cash position, following a $2.75 million public offering which the Company previously announced was completed in October 2015. The proceeds of the debt financing transaction, together with the public offering, will help advance the Company's lead antibody-based product HuMab-5B1, recently authorized by the U.S. Food and Drug Administration (FDA) to proceed with the first of two Phase 1 clinical trials, in 2016. The funds will also be used to advance other anti-body and diagnostic products in the pipeline in 2016.
MabVax Therapeutics Files IND for a Phase I Clinical Trial with 89Zr-HuMab-5B1
PR Newswire - Wed Jan 06, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for 89Zr-HuMab-5B1, the Company's fully human antibody product, as a new generation PET scan cancer imaging agent. Subject to FDA authorization to proceed, MabVax plans to initiate the Phase I clinical trial in patients with pancreatic cancer in early 2016.
Epithelial Ovarian Cancer - Pipeline Review, H2 2015
M2 - Thu Dec 17, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/62vzjr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 35 of the 60 Companies Featured in this Pipeline Review - AbbVie Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Bayer AG - Bionomics Limited - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Genor BioPharma Co., Ltd. - Glycotope GmbH - Hetero Drugs Limited - ImmunoGen, Inc. - Immunotope, Inc. - Incyte Corporation - Innate Immunotherapeutics Limited - Johnson & Johnson - Mabion SA - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mycenax Biotech Inc. - Novartis AG - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Prima BioMed Ltd. - Tesaro, Inc. For more information visit http://www.researchandmarkets.com/research/62vzjr/epithelial
PCYC: 261.25 (+1.70), TSRO: 42.07 (+0.41), CERU: 2.10 (-0.07), PFE: 34.75 (-0.04), INCY: 80.00 (+0.55), IMGN: 3.49 (-0.01), AMGN: 152.30 (+0.40), JNJ: 116.64 (+0.23), CLSN: 1.35 (unch), CLVS: 13.77 (+0.23), MRK: 57.50 (+1.41), AZN: 27.63 (+0.26), ABBV: 60.90 (+0.50), NVS: 76.89 (+0.51), XLRN: 36.30 (-0.50)
MabVax Therapeutics - "Insights on MabVax's HuMab 5B1 from the World Molecular Imaging Conference"
ACCESSWIRE - Wed Dec 02, 10:10AM CST
NEW YORK, NY / ACCESSWIRE / December 2, 2015 / MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Three Small Companies With Big Name Partnerships In Immuno-Oncology
ACCESSWIRE - Tue Dec 01, 10:17AM CST
CORAL GABLES, FL / ACCESSWIRE / December 1, 2015 / Over the last twelve months, many of the biggest players in biotech have inked partnerships or acquisitions to gain exposure to the immuno-oncology space, or stimulating the immune system to attack cancer. Pfizer Inc. (PFE), GlaxoSmithKline plc (GSK) and Celgene Corporation (CELG) have all committed significant capital this year. Analysts expect immuno-oncology to generate $35 billion sales before 2023, growing to account for 60% of the total cancer management space. The big names are not the only players, however. There are a number of smaller development stage biotechs with candidates in trials that could be the target of the next big acquisition deal, or become blockbuster therapies in their own right. Here's a look at three of them that already have big name partnerships.
PFE: 34.75 (-0.04), PPHM: 0.43 (-0.01), CTIC: 0.39 (-0.03), GSK: 40.57 (+0.53)
MabVax Therapeutics Launches Second Investigational Site with Sarah Cannon Research Institute in Ongoing Phase I Clinical Trial to Evaluate New Treatment for Pancreatic Cancer
PR Newswire - Mon Jun 13, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the initiation of a second investigational Phase I site for MVT-5873 (HuMab-5B1) with Sarah Cannon Research Institute through its network of research sites. The product is for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. In addition to the Sarah Cannon Research Institute at Tennessee Oncology site in Nashville, Tenn., patient enrollment in the Phase I trial is underway within Sarah Cannon Research Institute at Florida Cancer Specialists in Sarasota, Fla.
MabVax Therapeutics Expands Patient Enrollment in Phase I Trial for Treatment of Pancreatic Cancer to Memorial Sloan Kettering Cancer Center
PR Newswire - Tue Jun 07, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the initiation of patient enrollment at Memorial Sloan Kettering Cancer Center (MSK) in the Phase I clinical trial evaluating its leading clinical development product MVT-5873 (HuMab-5B1) as a therapeutic treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. This is the second investigational site in the Phase I trial with patient recruitment currently underway at the Sarah Cannon Research Institute in Nashville, TN. MabVax previously announced receipt of authorization to proceed on the Investigational New Drug (IND) application filed from U.S. Food and Drug Administration (FDA).
MabVax Therapeutics' Antibody Discovery Platform and HuMab-5B1 Cancer Therapeutic Featured in Presentation at America's Antibody Congress
PR Newswire - Thu May 19, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that Paul Maffuid, PhD, Executive Vice President of Research and Development, will discuss MabVax's unique approach to the discovery of fully human antibodies to cancer antigens and the resulting lead HuMab-5B1 clinical projects in a presentation at America's Antibody Congress in San Diego on May 19-20, 2016.
MabVax Therapeutics' HuMab-5B1 Cancer Therapeutic Featured in Presentation at AACR Special Meeting on Pancreatic Cancer
PR Newswire - Mon May 16, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that its lead cancer therapeutic HuMab-5B1 (MVT-5873) was featured in a poster presentation on May 13th at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, held in Orlando, Florida. MVT-5873 is currently being evaluated in an open-label, multicenter, dose-escalation Phase I clinical trial as a single agent and in combination with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.
MabVax Therapeutics' Fully Human Antibody Approach to Cancer Therapeutics and Imaging Featured in Three Presentations at AACR Annual Meeting in New Orleans
PR Newswire - Mon Apr 18, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that its fully human antibody approach to cancer therapeutics and imaging will be featured in three separate poster presentations at the American Association for Cancer Research (AACR) Annual Meeting currently underway in New Orleans.
MabVax Therapeutics Holdings Hires Paul Resnick, M.D. as Chief Business Officer
PR Newswire - Fri Apr 15, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the hiring of Paul Resnick, M.D., M.B.A. to the newly created position of Vice President and Chief Business Officer, responsible for corporate development, including engaging with large pharmaceutical and biotechnology companies on potential licensing and collaboration arrangements for our products under development.
MabVax Therapeutics Initiates Phase I Trial of HuMab-5B1 for Treatment of Pancreatic Cancer
PR Newswire - Mon Mar 21, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announced initiation of a phase I clinical trial of HuMab-5B1 for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. The CA19-9 target is expressed on more than 90% of pancreatic cancers and is a validated biomarker for the disease. The Company filed an Investigational New Drug (IND) application for this product on November 30, 2015 and received U.S. Food and Drug Administration (FDA) authorization to proceed with the study on December 24, 2015.
UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.80 (+0.19), CDXC: 5.07 (-0.24)
MabVax Therapeutics to Present at the ROTH Conference
PR Newswire - Thu Mar 10, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that President and Chief Executive Officer David Hansen is scheduled to present a corporate overview at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 11:00 a.m. Pacific time (2:00 p.m. Eastern time). The conference is being held at The Ritz Carlton Laguna Niguel hotel in Dana Point, Calif.
OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 4.80 (+0.19), CDXC: 5.07 (-0.24)
MabVax Therapeutics to Present at BIO CEO & Investor Conference
PR Newswire - Wed Feb 03, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that President and Chief Executive Officer David Hansen is scheduled to present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). The conference is being held at The Waldorf Astoria New York hotel in New York City.
MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer
PR Newswire - Mon Feb 01, 9:37AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration (FDA) authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. The Company filed an Investigational New Drug (IND) application for this trial with the FDA on December 29, 2015. MabVax previously announced receipt of FDA authorization for a Phase I trial with HuMab-5B1 as a therapeutic treatment for patients with pancreatic cancer, and patient enrollment in both Phase I trials is expected to commence in the first quarter of 2016.
World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zbk4w/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Small-Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Small-Cell Lung Cancer - Overview - Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis - Small-Cell Lung Cancer - Therapeutics under Development by Companies - Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Small-Cell Lung Cancer - Products under Development by Companies - Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Andarix Pharmaceuticals, Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - G1 Therapeutics, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Karyopharm Therapeutics, Inc. - Kolltan Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - MEI Pharma, Inc. - Merck & Co., Inc. - NanoSmart Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Novartis AG - Pfizer Inc. - Polaris Pharmaceuticals, Inc. - Rexahn Pharmaceuticals, Inc. - Spectrum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3z...lcell_lung
RNN: 0.26 (-0.01), PFE: 34.75 (-0.04), AMGN: 152.30 (+0.40), SPPI: 6.82 (unch), BIND: 0.42 (-0.01), LLY: 74.25 (+0.54), BMY: 71.73 (-0.84), GSK: 40.57 (+0.53), MEIP: 1.33 (+0.05), MRK: 57.50 (+1.41), ABBV: 60.90 (+0.50), NVS: 76.89 (+0.51), KPTI: 8.06 (+0.15), ARRY: 3.26 (+0.01), EXEL: 7.55 (+0.17)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
PCYC: 261.25 (+1.70), AMPE: 3.50 (+0.06), GSK: 40.57 (+0.53), MEIP: 1.33 (+0.05), AAAP: 29.00 (-0.57), MACK: 6.33 (+0.02), PGNX: 4.74 (+0.11), BLCM: 12.74 (+0.30), CYCC: 5.33 (-0.43), RXDX: 5.43 (-0.17), MRK: 57.50 (+1.41), AZN: 27.63 (+0.26), JUNO: 42.94 (-0.15), CBLI: 2.58 (-0.03), NVS: 76.89 (+0.51), CELGZ: 1.33 (-0.07)
MabVax Therapeutics Holdings Executes a Debt Facility for up to $10 million
PR Newswire - Tue Jan 19, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company announced today that it has closed on the first part of a financing agreement with a leading life sciences and healthcare lender. The financing agreement will provide the Company with up to $10 million in senior secured debt financing. The Company received an initial loan of $5 million, before approximately $381,000 in issuances costs, with an additional $5 million to be released contingent upon achieving certain milestones. The net proceeds of the initial tranche of debt financing will supplement the Company's cash position, following a $2.75 million public offering which the Company previously announced was completed in October 2015. The proceeds of the debt financing transaction, together with the public offering, will help advance the Company's lead antibody-based product HuMab-5B1, recently authorized by the U.S. Food and Drug Administration (FDA) to proceed with the first of two Phase 1 clinical trials, in 2016. The funds will also be used to advance other anti-body and diagnostic products in the pipeline in 2016.
MabVax Therapeutics Files IND for a Phase I Clinical Trial with 89Zr-HuMab-5B1
PR Newswire - Wed Jan 06, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for 89Zr-HuMab-5B1, the Company's fully human antibody product, as a new generation PET scan cancer imaging agent. Subject to FDA authorization to proceed, MabVax plans to initiate the Phase I clinical trial in patients with pancreatic cancer in early 2016.
Epithelial Ovarian Cancer - Pipeline Review, H2 2015
M2 - Thu Dec 17, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/62vzjr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 35 of the 60 Companies Featured in this Pipeline Review - AbbVie Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Bayer AG - Bionomics Limited - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Genor BioPharma Co., Ltd. - Glycotope GmbH - Hetero Drugs Limited - ImmunoGen, Inc. - Immunotope, Inc. - Incyte Corporation - Innate Immunotherapeutics Limited - Johnson & Johnson - Mabion SA - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mycenax Biotech Inc. - Novartis AG - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Prima BioMed Ltd. - Tesaro, Inc. For more information visit http://www.researchandmarkets.com/research/62vzjr/epithelial
PCYC: 261.25 (+1.70), TSRO: 42.07 (+0.41), CERU: 2.10 (-0.07), PFE: 34.75 (-0.04), INCY: 80.00 (+0.55), IMGN: 3.49 (-0.01), AMGN: 152.30 (+0.40), JNJ: 116.64 (+0.23), CLSN: 1.35 (unch), CLVS: 13.77 (+0.23), MRK: 57.50 (+1.41), AZN: 27.63 (+0.26), ABBV: 60.90 (+0.50), NVS: 76.89 (+0.51), XLRN: 36.30 (-0.50)
MabVax Therapeutics - "Insights on MabVax's HuMab 5B1 from the World Molecular Imaging Conference"
ACCESSWIRE - Wed Dec 02, 10:10AM CST
NEW YORK, NY / ACCESSWIRE / December 2, 2015 / MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Three Small Companies With Big Name Partnerships In Immuno-Oncology
ACCESSWIRE - Tue Dec 01, 10:17AM CST
CORAL GABLES, FL / ACCESSWIRE / December 1, 2015 / Over the last twelve months, many of the biggest players in biotech have inked partnerships or acquisitions to gain exposure to the immuno-oncology space, or stimulating the immune system to attack cancer. Pfizer Inc. (PFE), GlaxoSmithKline plc (GSK) and Celgene Corporation (CELG) have all committed significant capital this year. Analysts expect immuno-oncology to generate $35 billion sales before 2023, growing to account for 60% of the total cancer management space. The big names are not the only players, however. There are a number of smaller development stage biotechs with candidates in trials that could be the target of the next big acquisition deal, or become blockbuster therapies in their own right. Here's a look at three of them that already have big name partnerships.
PFE: 34.75 (-0.04), PPHM: 0.43 (-0.01), CTIC: 0.39 (-0.03), GSK: 40.57 (+0.53)
